Overview and Outcomes of Patients Hospitalised with COVID-19 Pneumonia in Rīga East University Hospital-Reference-Cited by-同舟云学术

Overview and Outcomes of Patients Hospitalised with COVID-19 Pneumonia in Rīga East University Hospital

Published:2024-02-01 Issue:1 Volume:78 Page:10-15
ISSN:2255-890X
Container-title:Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
language:en
Short-container-title:

Author:

Rugājs Reinis¹²,Madelāne Monta¹³,Ivanovs Andrejs⁴,Vīksna Ludmila¹³

Affiliation:

1. Rīga East University Hospital , Rīga , , Latvia

2. Faculty of Residency , Rīga Stradiņš University , Rīga , , Latvia

3. Department of Infectology , Rīga Stradiņš University, Rīga , , Latvia

4. Statistics Laboratory , Rīga Stradiņš University , Rīga , , Latvia

Abstract

Abstract The COVID-19 pandemic is still a burden to the global health care system, affecting its capacity to maintain essential health services. Even though specific treatment and prevention options are available, the SARS-CoV-2 virus keeps accumulating mutations over time and challenging the efficiency of vaccines, causing new outbreaks and increasing hospitalisation. Early studies suggest that mortality from COVID-19 is increased by age and certain comorbidities. Thus, the goal of this study was to analyse patients hospitalised with COVID-19 pneumonia in terms of age, sex, and comorbidities. Additionally, the influence of treatment with Remdesivir and vaccination on hospitalisation duration and disease outcome was also analysed. The results showed that lethal disease outcome is mainly increased by age and gender, where older and male patients are at a higher risk. There were less deaths in patients with primary arterial hypertension. Other comorbidities did not have a statistically significant influence on disease outcome. Among those who survived, a higher number of patients had been treated with Remdesivir. Vaccination did not have an impact on disease outcome. It could be concluded that older and male patients are the risk group with a worse disease outcome. Treatment with Remdesivir shows a positive effect on disease outcome, although further detailed analysis is necessary.

Publisher

Walter de Gruyter GmbH

Link

https://www.sciendo.com/pdf/10.2478/prolas-2024-0002

Reference27 articles.

1. Aleem, A., Akbar Samad, A. B., Slenker, A. K. (2022). Emerging variants of SARS-CoV-2 and novel therapeutics gainst coronavirus (COVID-19). In: StatPearls. StatPearls Publishing.

2. Almehdi, A. M., Khoder, G., Alchakee, A. S., Alsayyid, A. T., Sarg, N. H., Soliman, S. (2021). SARS-CoV-2 spike protein: Pathogenesis, vaccines, and potential therapies. Infection, 49 (5), 855–876. https://doi.org/10.1007/s15010-021-01677-8.

3. Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S. et al. (2020). Remdesivir for the treatment of covid-19 — final report. New Engl. J. Med., 383 (19), 1813–1826. https://doi.org/10.1056/NEJMoa2007764.

4. Bhaskaran, K., Bacon, S., Evans, S. J., Bates, C. J., Rentsch, C. T., MacKenna, B., Tomlinson, L., Walker, A. J., Schultze, A., Morton, C. E. et al. (2021). Factors associated with deaths due to COVID-19 versus other causes: Population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. The Lancet Regional Health. Europe, 6, 100109. https://doi.org/10.1016/j.lanepe.2021.100109.

5. Bonanad, C., García-Blas, S., Tarazona-Santabalbina, F., Sanchis, J., Bertomeu-González, V., Fácila, L., Ariza, A., Núñez, J., Cordero, A. (2020). The effect of age on mortality in patients with COVID-19: A meta-analysis with 611,583 subjects. J. Amer. Med. Dir. Assoc., 21 (7), 915–918. https://doi.org/10.1016/j.jamda.2020.05.045.